5-aminosalicylic acid

This page contains recent news articles, when available, and an overview of 5-aminosalicylic acid but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 ... - ‎Oct 26, 2009‎
Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA) persistency analyses at ACG ... Reuters

Real-World Patient Experiences on Medications for Chronic Conditions ... - ‎Oct 26, 2009‎
...perceptions and experiences of patients beginning and continuing a new course of 5-aminosalicylic acid (5-ASA), the mainstay of treatment for UC. ... Reuters

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.